|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prostate cancer: Send away the PSA?
Lancet. 380:3072012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marugame T and Katanoda K: International
comparisons of cumulative risk of breast and prostate cancer, from
cancer incidence in five continents Vol. VIII. Jpn J Clin Oncol.
36:399–400. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee J, Demissie K, Lu SE and Rhoads GG:
Cancer incidence among Korean-American immigrants in the United
States and native Koreans in South Korea. Cancer Control. 14:78–85.
2007.PubMed/NCBI
|
|
5
|
Sottnik JL, Dai J, Zhang H, Campbell B and
Keller ET: Tumor-induced pressure in the bone microenvironment
causes osteocytes to promote the growth of prostate cancer bone
metastases. Cancer Res. 75:2151–2158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fan L, Peng G, Sahgal N, Fazli L, Gleave
M, Zhang Y, Hussain A and Qi J: Regulation of c-Myc expression by
the histone demethylase JMJD1A is essential for prostate cancer
cell growth and survival. Oncogene. 35:2441–2452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee S, Luong R, Johnson DT, Cunha GR,
Rivina L, Gonzalgo ML and Sun Z: Androgen signaling is a
confounding factor for β-catenin-mediated prostate tumorigenesis.
Oncogene. 35:702–714. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Bono JS, Oudard S, Ozguroglu M, Hansen
S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L,
et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: A randomised open-label trial. Lancet. 376:1147–1154.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fizazi K, Carducci M, Smith M, Damião R,
Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al:
Denosumab versus zoledronic acid for treatment of bone metastases
in men with castration-resistant prostate cancer: A randomised,
double-blind study. Lancet. 377:813–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Laderach DJ, Gentilini LD, Giribaldi L,
Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G,
Mazza O, et al: A unique galectin signature in human prostate
cancer progression suggests galectin-1 as a key target for
treatment of advanced disease. Cancer Res. 73:86–96. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Trewartha D and Carter K: Advances in
prostate cancer treatment. Nat Rev Drug Discov. 12:823–824. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Violette PD, Agoritsas T, Alexander P,
Riikonen J, Santti H, Agarwal A, Bhatnagar N, Dahm P, Montori V,
Guyatt GH and Tikkinen KA: Decision aids for localized prostate
cancer treatment choice: Systematic review and meta-analysis. CA
Cancer J Clin. 65:239–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Locke JA, Guns ES, Lubik AA, Adomat HH,
Hendy SC, Wood CA, Ettinger SL, Gleave ME and Nelson CC: Androgen
levels increase by intratumoral de novo steroidogenesis during
progression of castration-resistant prostate cancer. Cancer Res.
68:6407–6415. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gundem G, Van Loo P, Kremeyer B,
Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM,
Högnäs G, Annala M, et al: The evolutionary history of lethal
metastatic prostate cancer. Nature. 520:353–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee KC, Sud S, Meyer CR, Moffat BA,
Chenevert TL, Rehemtulla A, Pienta KJ and Ross BD: An imaging
biomarker of early treatment response in prostate cancer that has
metastasized to the bone. Cancer Res. 67:3524–3528. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stephan C, Cammann H, Meyer HA, Lein M and
Jung K: PSA and new biomarkers within multivariate models to
improve early detection of prostate cancer. Cancer Lett. 249:18–29.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barbieri CE, Baca SC, Lawrence MS,
Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van
Allen E, Stransky N, et al: Exome sequencing identifies recurrent
SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet.
44:685–689. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cristofanilli M, Budd GT, Ellis MJ,
Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ,
Terstappen LW and Hayes DF: Circulating tumor cells, disease
progression and survival in metastatic breast cancer. N Engl J Med.
351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Bono JS, Scher HI, Montgomery RB,
Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ
and Raghavan D: Circulating tumor cells predict survival benefit
from treatment in metastatic castration-resistant prostate cancer.
Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scher HI, Jia X, de Bono JS, Fleisher M,
Pienta KJ, Raghavan D and Heller G: Circulating tumour cells as
prognostic markers in progressive, castration-resistant prostate
cancer: a reanalysis of IMMC38 trial data. Lancet Oncol.
10:233–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Olmos D, Arkenau HT, Ang JE, Ledaki I,
Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, et al:
Circulating tumour cell (CTC) counts as intermediate end points in
castration-resistant prostate cancer (CRPC): A single-centre
experience. Ann Oncol. 20:27–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Danila DC, Heller G, Gignac GA,
Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson
S, Fleisher M and Scher HI: Circulating tumor cell number and
prognosis in progressive castration-resistant prostate cancer. Clin
Cancer Res. 13:7053–7058. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen JF, Ho H, Lichterman J, Lu YT, Zhang
Y, Garcia MA, Chen SF, Liang AJ, Hodara E, Zhau HE, et al:
Subclassification of prostate cancer circulating tumor cells by
nuclear size reveals very small nuclear circulating tumor cells in
patients with visceral metastases. Cancer. 121:3240–3251. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dorff TB, Groshen S, Tsao-Wei DD, Xiong S,
Gross ME, Vogelzang N, Quinn DI and Pinski JK: A Phase II trial of
a combination herbal supplement for men with biochemically
recurrent prostate cancer. Prostate Cancer Prostatic Dis.
17:359–365. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rossi E, Rugge M, Facchinetti A, Pizzi M,
Nardo G, Barbieri V, Manicone M, De Faveri S, Scaini M Chiara,
Basso U, et al: Retaining the long-survive capacity of circulating
tumor cells (CTCs) followed by xeno-transplantation: Not only from
metastatic cancer of the breast but also of prostate cancer
patients. Oncoscience. 1:49–56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paris PL, Kobayashi Y, Zhao Q, Zeng W,
Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, et al:
Functional phenotyping and genotyping of circulating tumor cells
from patients with castration resistant prostate cancer. Cancer
Lett. 277:164–173. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Helzer KT, Barnes HE, Day L, Harvey J,
Billings PR and Forsyth A: Circulating tumor cells are
transcriptionally similar to the primary tumor in a murine prostate
model. Cancer Res. 69:7860–7866. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lohr JG, Adalsteinsson VA, Cibulskis K,
Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ,
Shalek AK, Satija R, et al: Whole-exome sequencing of circulating
tumor cells provides a window into metastatic prostate cancer. Nat
Biotechnol. 32:479–484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu M, Bardia A, Aceto N, Bersani F, Madden
MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, et al:
Cancer therapy. Ex vivo culture of circulating breast tumor cells
for individualized testing of drug susceptibility. Science.
345:216–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z,
Zong C, Bai H, Chapman AR, Zhao J, et al: Reproducible copy number
variation patterns among single circulating tumor cells of lung
cancer patients. Proc Natl Acad Sci USA. 110:pp. 21083–21088. 2013;
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Steinert G, Schölch S, Niemietz T, Iwata
N, García SA, Behrens B, Voigt A, Kloor M, Benner A, Bork U, et al:
Immune escape and survival mechanisms in circulating tumor cells of
colorectal cancer. Cancer Res. 74:1694–1704. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Anantharaman A and Friedlander TW: A
stepping stone toward personalized oncology: Genomic analysis of
circulating tumor cells to guide management of metastatic
castration-resistant prostate cancer. Eur Urol. 68:946–948. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Steinestel J, Luedeke M, Arndt A,
Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel
K and Schrader AJ: Detecting predictive androgen receptor
modifications in circulating prostate cancer cells. Oncotarget. Apr
23–2015.(Epub ahead of print).
|
|
35
|
Liu SV, Tsao-Wei DD, Xiong S, Groshen S,
Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV and Pinski
JK: Phase I, dose-escalation study of the targeted cytotoxic LHRH
analog AEZS-108 in patients with castration- and taxane-resistant
prostate cancer. Clin Cancer Res. 20:6277–6283. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee RJ, Saylor PJ, Michaelson MD,
Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran
S, Haber DA, et al: A dose-ranging study of cabozantinib in men
with castration-resistant prostate cancer and bone metastases. Clin
Cancer Res. 19:3088–3094. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Coumans FA, van Dalum G, Beck M and
Terstappen LW: Filter characteristics influencing circulating tumor
cell enrichment from whole blood. PLoS One. 8:e617702013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gleghorn JP, Pratt ED, Denning D, Liu H,
Bander NH, Tagawa ST, Nanus DM, Giannakakou PA and Kirby BJ:
Capture of circulating tumor cells from whole blood of prostate
cancer patients using geometrically enhanced differential
immunocapture (GEDI) and a prostate-specific antibody. Lab Chip.
10:27–29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu L, Mao X, Imrali A, Syed F, Mutsvangwa
K, Berney D, Cathcart P, Hines J, Shamash J and Lu YJ: Optimization
and evaluation of a novel size based circulating tumor cell
isolation system. PLoS One. 10:e01380322015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Joshi P, Jacobs B, Derakhshan A, Moore LR,
Elson P, Triozzi PL, Borden E and Zborowski M: Enrichment of
circulating melanoma cells (CMCs) using negative selection from
patients with metastatic melanoma. Oncotarget. 5:2450–2461. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Toss A, Mu Z, Fernandez S and
Cristofanilli M: CTC enumeration and characterization: Moving
toward personalized medicine. Ann Transl Med. 2:108.
2014.PubMed/NCBI
|
|
43
|
Qin X, Park S, Duffy SP, Matthews K, Ang
RR, Todenhöfer T, Abdi H, Azad A, Bazov J, Chi KN, et al: Size and
deformability based separation of circulating tumor cells from
castrate resistant prostate cancer patients using resettable cell
traps. Lab Chip. 15:2278–2286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sunyoung P, Ang RR, Duffy SP, Bazov J, Chi
KN, Black PC and Ma H: Morphological differences between
circulating tumor cells from prostate cancer patients and cultured
prostate cancer cells. PLoS One. 9:e852642014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rosenberg R, Gertler R, Friederichs J,
Fuehrer K, Dahm M, Phelps R, Thorban S, Nekarda H and Siewert JR:
Comparison of two density gradient centrifugation systems for the
enrichment of disseminated tumor cells in blood. Cytometry.
49:150–158. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Woelfle U, Breit E, Zafrakas K, Otte M,
Schubert F, Müller V, Izbicki JR, Löning T and Pantel K:
Bi-specific immunomagnetic enrichment of micrometastatic tumour
cell clusters from bone marrow of cancer patients. J Immunol
Methods. 300:136–145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Coumans FA, Doggen CJ, Attard G, de Bono
JS and Terstappen LW: All circulating EpCAM+CK+CD45-objects predict
overall survival in castration-resistant prostate cancer. Ann
Oncol. 21:1851–1857. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Riethdorf S, Fritsche H, Müller V, Rau T,
Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, et al:
Detection of circulating tumor cells in peripheral blood of
patients with metastatic breast cancer: A validation study of the
CellSearch system. Clin Cancer Res. 13:920–928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dotan E, Cohen SJ, Alpaugh KR and Meropol
NJ: Circulating tumor cells: Evolving evidence and future
challenges. Oncologist. 14:1070–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pavese JM and Bergan RC: Circulating tumor
cells exhibit a biologically aggressive cancer phenotype
accompanied by selective resistance to chemotherapy. Cancer Lett.
352:179–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bitting RL, Boominathan R, Rao C, Kemeny
G, Foulk B, Garcia-Blanco MA, Connelly M and Armstrong AJ:
Development of a method to isolate circulating tumor cells using
mesenchymal-based capture. Methods. 64:129–136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Santana SM, Liu H, Bander NH, Gleghorn JP
and Kirby BJ: Immunocapture of prostate cancer cells by use of
anti-PSMA antibodies in microdevices. Biomed Microdevices.
14:401–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Witzig TE, Bossy B, Kimlinger T, Roche PC,
Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J
and Bauer KD: Detection of circulating cytokeratin-positive cells
in the blood of breast cancer patients using immunomagnetic
enrichment and digital microscopy. Clin Cancer Res. 8:1085–1091.
2002.PubMed/NCBI
|
|
54
|
Lu YT, Zhao L, Shen Q, Garcia MA, Wu D,
Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, et al: NanoVelcro Chip
for CTC enumeration in prostate cancer patients. Methods.
64:144–152. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nellore BP Viraka, Kanchanapally R,
Pramanik A, Sinha SS, Chavva SR, Hamme A II and Ray PC:
Aptamer-conjugated graphene oxide membranes for highly efficient
capture and accurate identification of multiple types of
circulating tumor cells. Bioconjug Chem. 26:235–242. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Antfolk M, Magnusson C, Augustsson P,
Lilja H and Laurell T: Acoustofluidic, label-free separation and
simultaneous concentration of rare tumor cells from white blood
cells. Anal Chem. 87:9322–9328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Huang SB, Wu MH, Lin YH, Hsieh CH, Yang
CL, Lin HC, Tseng CP and Lee GB: High-purity and label-free
isolation of circulating tumor cells (CTCs) in a microfluidic
platform by using optically-induced-dielectrophoretic (ODEP) force.
Lab on A Chip. 13:1371–1383. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ozkumur E, Shah AM, Ciciliano JC, Emmink
BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J,
et al: Inertial focusing for tumor antigen-dependent and
-independent sorting of rare circulating tumor cells. Sci Transl
Med. 5:179ra472013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Autebert J, Coudert B, Champ J, Saias L,
Guneri ET, Lebofsky R, Bidard FC, Pierga JY, Farace F, Descroix S,
et al: High purity microfluidic sorting and analysis of circulating
tumor cells: Towards routine mutation detection. Lab Chip.
15:2090–2101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Antfolk M, Antfolk C, Lilja H, Laurell T
and Augustsson P: A single inlet two-stage acoustophoresis chip
enabling tumor cell enrichment from white blood cells. Lab Chip.
15:2102–2109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sarioglu AF, Aceto N, Kojic N, Donaldson
MC, Zeinali M, Hamza B, Engstrom A, Zhu H, Sundaresan TK, Miyamoto
DT, et al: A microfluidic device for label-free, physical capture
of circulating tumor cell clusters. Nat Methods. 12:685–691. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hou JM, Krebs M, Ward T, Morris K, Sloane
R, Blackhall F and Dive C: Circulating tumor cells, enumeration and
beyond. Cancers (Basel). 2:1236–1250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Stott SL, Lee RJ, Nagrath S, Yu M,
Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z,
et al: Isolation and characterization of circulating tumor cells
from patients with localized and metastatic prostate cancer. Sci
Transl Med. 2:25ra232010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kirby BJ, Jodari M, Loftus MS, Gakhar G,
Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP,
et al: Functional characterization of circulating tumor cells with
a prostate-cancer-specific microfluidic device. PLoS One.
7:e359762012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Friedlander TW, Ngo VT, Dong H,
Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ,
Chen WT and Paris PL: Detection and characterization of invasive
circulating tumor cells derived from men with metastatic
castration-resistant prostate cancer. Int J Cancer. 134:2284–2293.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Tseng JY, Yang CY, Liang SC, Liu RS, Jiang
JK and Lin CH: Dynamic changes in numbers and properties of
circulating tumor cells and their potential applications. Cancers
(Basel). 6:2369–2386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Myung JH, Gajjar KA, Chen J, Molokie RE
and Hong S: Differential detection of tumor cells using a
combination of cell rolling, multivalent binding, and multiple
antibodies. Anal Chem. 86:6088–6094. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gerges N, Rak J and Jabado N: New
technologies for the detection of circulating tumour cells. Br Med
Bull. 94:49–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Helo P, Cronin AM, Danila DC, Wenske S,
Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen RM, Pettersson
K, Chun FK, et al: Circulating prostate tumor cells detected by
reverse transcription-PCR in men with localized or
castration-refractory prostate cancer: Concordance with CellSearch
assay and association with bone metastases and with survival. Clin
Chem. 55:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gervasoni A, Muñoz RM Monasterio, Wengler
GS, Rizzi A, Zaniboni A and Parolini O: Molecular signature
detection of circulating tumor cells using a panel of selected
genes. Cancer Lett. 263:267–279. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Stott SL, Hsu CH, Tsukrov DI, Yu M,
Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK,
et al: Isolation of circulating tumor cells using a
microvortex-generating herringbone-chip. Proc Natl Acad Sci USA.
107:pp. 18392–18397. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yates DR, Rouprêt M, Drouin SJ, Comperat
E, Ricci S, Lacave R, Sèbe P, Cancel-Tassin G, Bitker MO and
Cussenot O: Quantitative RT-PCR analysis of PSA and
prostate-specific membrane antigen mRNA to detect circulating tumor
cells improves recurrence-free survival nomogram prediction after
radical prostatectomy. Prostate. 72:1382–1388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Mohamadi RM, Ivanov I, Stojcic J, Nam RK,
Sargent EH and Kelley SO: Sample-to-answer isolation and mRNA
profiling of circulating tumor cells. Anal Chem. 87:6258–6264.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Jiang Y, Palma JF, Agus DB, Wang Y and
Gross ME: Detection of androgen receptor mutations in circulating
tumor cells in castration-resistant prostate cancer. Clin Chem.
56:1492–1495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Dijkstra S, Leyten GH, Jannink SA, de Jong
H, Mulders PF, van Oort IM and Schalken JA: KLK3, PCA3 and
TMPRSS2-ERG expression in the peripheral blood mononuclear cell
fraction from castration-resistant prostate cancer patients and
response to docetaxel treatment. Prostate. 74:1222–1230. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Antonarakis ES, Lu C, Wang H, Luber B,
Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et
al: AR-V7 and resistance to enzalutamide and abiraterone in
prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Panteleakou Z, Lembessis P, Sourla A,
Pissimissis N, Polyzos A, Deliveliotis C and Koutsilieris M:
Detection of circulating tumor cells in prostate cancer patients:
Methodological pitfalls and clinical relevance. Mol Med.
15:101–114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sioss JA, Bhiladvala RB, Pan W, Li M,
Patrick S, Xin P, Dean SL, Keating CD, Mayer TS and Clawson GA:
Nanoresonator chip-based RNA sensor strategy for detection of
circulating tumor cells: Response using PCA3 as a prostate cancer
marker. Nanomedicine. 8:1017–1025. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Ivanov I, Stojcic J, Stanimirovic A,
Sargent E, Nam RK and Kelley SO: Chip-based nanostructured sensors
enable accurate identification and classification of circulating
tumor cells in prostate cancer patient blood samples. Anal Chem.
85:398–403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gu Y, Ju C, Li Y, Shang Z, Wu Y, Jia Y and
Niu Y: Detection of circulating tumor cells in prostate cancer
based on carboxylated graphene oxide modified light addressable
potentiometric sensor. Biosens Bioelectron. 66:24–31. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kerr BA, Miocinovic R, Smith AK, West XZ,
Watts KE, Alzayed AW, Klink JC, Mir MC, Sturey T, Hansel DE, et al:
CD117+ cells in the circulation are predictive of advanced prostate
cancer. Oncotarget. 6:1889–1897. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang H, Yang M, Xu J, Zou B, Zhou Q, Bian
J and Wang X: Survivin mRNA-circulating tumor cells are associated
with prostate cancer metastasis. Tumour Biol. 37:723–727. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Danila DC, Anand A, Schultz N, Heller G,
Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H and Scher HI:
Analytic and clinical validation of a prostate cancer-enhanced
messenger RNA detection assay in whole blood as a prognostic
biomarker for survival. Eur Urol. 65:1191–1197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Moreno JG, Miller MC, Gross S, Allard WJ,
Gomella LG and Terstappen LW: Circulating tumor cells predict
survival in patients with metastatic prostate cancer. Urology.
65:713–718. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Scher HI, Jia X, de Bono JS, Fleisher M,
Pienta KJ, Raghavan D and Heller G: Circulating tumour cells as
prognostic markers in progressive, castration-resistant prostate
cancer: A reanalysis of IMMC38 trial data. Lancet Oncol.
10:233–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Thalgott M, Heck MM, Eiber M, Souvatzoglou
M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M,
Gschwend JE, et al: Circulating tumor cells versus objective
response assessment predicting survival in metastatic
castration-resistant prostate cancer patients treated with
docetaxel chemotherapy. J Cancer Res Clin Oncol. 141:1457–1464.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Marín-Aguilera M, Reig Ò, Lozano JJ,
Jiménez N, García-Recio S, Erill N, Gaba L, Tagliapietra A, Ortega
V, Carrera G, et al: Molecular profiling of peripheral blood is
associated with circulating tumor cells content and poor survival
in metastatic castration-resistant prostate cancer. Oncotarget.
6:10604–10616. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Goldkorn A, Ely B, Tangen CM, Tai YC, Xu
T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, et
al: Circulating tumor cell telomerase activity as a prognostic
marker for overall survival in SWOG 0421: A phase III metastatic
castration resistant prostate cancer trial. Int J Cancer.
136:1856–1862. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Thalgott M, Rack B, Maurer T, Souvatzoglou
M, Eiber M, Kreß V, Heck MM, Andergassen U, Nawroth R, Gschwend JE
and Retz M: Detection of circulating tumor cells in different
stages of prostate cancer. J Cancer Res Clin Oncol. 139:755–763.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Loh J, Jovanovic L, Lehman M, Capp A,
Pryor D, Harris M, Nelson C and Martin J: Circulating tumor cell
detection in high-risk non-metastatic prostate cancer. J Cancer Res
Clin Oncol. 140:2157–2162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Davis JW, Nakanishi H, Kumar VS,
Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T and
Babaian RJ: Circulating tumor cells in peripheral blood samples
from patients with increased serum prostate specific antigen:
Initial results in early prostate cancer. J Urol. 179:2187–2191.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kolostova K, Broul M, Schraml J, Cegan M,
Matkowski R, Fiutowski M and Bobek V: Circulating tumor cells in
localized prostate cancer: Isolation, cultivation in vitro and
relationship to T-stage and Gleason score. Anticancer Res.
34:3641–3646. 2014.PubMed/NCBI
|
|
93
|
Bitting RL, Healy P, Halabi S, George DJ,
Goodin M and Armstrong AJ: Clinical phenotypes associated with
circulating tumor cell enumeration in metastatic
castration-resistant prostate cancer. Urol Oncol. 33:110.e1–9.
2015. View Article : Google Scholar
|
|
94
|
Schoenborn JR, Nelson P and Fang M:
Genomic profiling defines subtypes of prostate cancer with the
potential for therapeutic stratification. Clin Cancer Res.
19:4058–4066. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Chen CL, Mahalingam D, Osmulski P, Jadhav
RR, Wang CM, Leach RJ, Chang TC, Weitman SD, Kumar AP, Sun L, et
al: Single-cell analysis of circulating tumor cells identifies
cumulative expression patterns of EMT-related genes in metastatic
prostate cancer. Prostate. 73:813–826. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Osmulski P, Mahalingam D, Gaczynska ME,
Liu J, Huang S, Horning AM, Wang CM, Thompson IM, Huang TH and Chen
CL: Nanomechanical biomarkers of single circulating tumor cells for
detection of castration resistant prostate cancer. Prostate.
74:1297–1307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Boegemann M, Schrader AJ, Krabbe LM and
Herrmann E: Present, emerging and possible future biomarkers in
castration resistant prostate cancer (CRPC). Curr Cancer Drug
Targets. 15:243–255. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Stratton MR: Exploring the genomes of
cancer cells: Progress and promise. Science. 331:1553–1558. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Pantel K, Brakenhoff RH and Brandt B:
Detection, clinical relevance and specific biological properties of
disseminating tumour cells. Nat Rev Cancer. 8:329–340. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Alix-Panabières C, Schwarzenbach H and
Pantel K: Circulating tumor cells and circulating tumor DNA. Annu
Rev Med. 63:199–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Wang J, McGuire TR, Britton HC, Schwarz
JK, Loberiza FR Jr, Meza JL and Talmadge JE: Lenalidomide and
cyclophosphamide immunoregulation in patients with metastatic,
castration-resistant prostate cancer. Clin Exp Metastasis.
32:111–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wilbaux M, Tod M, De Bono J, Lorente D,
Mateo J, Freyer G, You B and Hénin E: A joint model for the
kinetics of CTC count and PSA concentration during treatment in
metastatic castration-resistant prostate cancer. CPT
Pharmacometrics Syst Pharmacol. 4:277–285. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Danila DC, Anand A, Sung CC, Heller G,
Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M and
Scher HI: TMPRSS2-ERG status in circulating tumor cells as a
predictive biomarker of sensitivity in castration-resistant
prostate cancer patients treated with abiraterone acetate. Eur
Urol. 60:897–904. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Smith MR, Sweeney CJ, Corn PG, Rathkopf
DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor
AO, et al: Cabozantinib in chemotherapy-pretreated metastatic
castration-resistant prostate cancer: Results of a phase II
nonrandomized expansion study. J Clin Oncol. 32:3391–3399. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dago AE, Stepansky A, Carlsson A, Luttgen
M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross ME,
et al: Rapid phenotypic and genomic change in response to
therapeutic pressure in prostate cancer inferred by high content
analysis of single circulating tumor cells. PLoS One.
9:e1017772014. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Reyes EE, VanderWeele DJ, Isikbay M,
Duggan R, Campanile A, Stadler WM, Griend DJ Vander and Szmulewitz
RZ: Quantitative characterization of androgen receptor protein
expression and cellular localization in circulating tumor cells
from patients with metastatic castration-resistant prostate cancer.
J Transl Med. 12:3132014. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Antonarakis ES, Lu C, Luber B, Wang H,
Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA,
et al: Androgen receptor splice variant 7 and efficacy of taxane
chemotherapy in patients with metastatic castration-resistant
prostate cancer. JAMA Oncol. 1:582–591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Onstenk W, Sieuwerts AM, Kraan J, Van M,
Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B,
Dirix LY, et al: Efficacy of cabazitaxel in castration-resistant
prostate cancer is independent of the presence of AR-V7 in
circulating tumor cells. Eur Urol. 68:939–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Bichsel CA, Gobaa S, Kobel S, Secondini C,
Thalmann GN, Cecchini MG and Lutolf MP: Diagnostic microchip to
assay 3D colony-growth potential of captured circulating tumor
cells. Lab Chip. 12:2313–2316. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Gao D, Vela I, Sboner A, Iaquinta PJ,
Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora
VK, et al: Organoid cultures derived from patients with advanced
prostate cancer. Cell. 159:176–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Miyamoto DT, Zheng Y, Wittner BS, Lee RJ,
Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, et
al: RNA-Seq of single prostate CTCs implicates noncanonical Wnt
signaling in antiandrogen resistance. Science. 349:1351–1356. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Mitchell MJ, Wayne E, Rana K, Schaffer CB
and King MR: TRAIL-coated leukocytes that kill cancer cells in the
circulation. Proc Natl Acad Sci USA. 111:pp. 930–935. 2014;
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kim G and Gaitas A: Extracorporeal
photo-immunotherapy for circulating tumor cells. PLoS One.
10:e01272192015. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Prostate cancer: Send away the PSA? Cancer
Discov. 5:570–571. 2015.
|
